Navigation Links
Cellular Dynamics International Scientists Report on Efficient Method to Produce Footprint-Free Induced Pluripotent Stem Cells (iPSCs) Under Feeder-Free Conditions
Date:3/4/2011

MADISON, Wis., March 4, 2011 /PRNewswire/ -- Cellular Dynamics International (CDI), the world's largest producer of human tissue cells for drug discovery and safety testing, today announced the publication of research demonstrating an efficient and scalable method of creating DNA integration-free, or footprint-free, induced pluripotent stem cells (iPSCs) under a feeder-free condition using chemically defined media.  This method, published on March 1 in PLoS ONE, will likely be valuable for the production of clinical-grade human iPSCs.

Junying Yu, Senior Director, Advanced Development Programs, and lead author of the paper, and her colleagues at CDI improved efficiency over her previously published method that resulted in exogenous DNA-free iPSCs by employing a cocktail containing four small molecules and cultured in chemically defined media free of feeder cells.  The addition of small molecules significantly improved episomal reprogramming efficiency.  Elimination of feeder cells and the use of chemically defined media for both the derivation and culture of footprint-free iPSCs bring the reprogramming technology one step closer to clinical applications.  In addition, the feeder cells represent a source of variability.  Eliminating feeder cells makes the process more amenable to industrialization.  The method was successfully applied and optimized for several cell types including human skin fibroblasts, adipose tissue-derived cells and cord blood cells.

"This publication underscores CDI's commitment to industrialized human biology," said Dr. Yu. "This method enables efficient, safe, large scale derivation of iPSCs for research applications and sets the stage for potential clinical use in the future."

"I wish to congratulate Dr. Yu on her most recent publication.  Her work brings us one step closer to the use of iPSC technology in medical treatment," said Robert Palay, CEO and chairman of CDI.  

Chris Parker, Chief Commercial Officer of CDI, added, "Cellular Dynamics is focused on optimizing processes for manufacturing human iPSCs and human differentiated cells for use by the biomedical community.  We have demonstrated that we can manufacture human iPSCs and our human iCell® Cardiomyocytes in the quantity, quality and purity required by our pharmaceutical customers for their drug discovery and toxicity testing programs.  We have other cell types, such as hepatocytes, neurons and blood vessel cells in development for these uses as well.  iPSCs and the human cells derived from them have potential applicability as therapeutics.  However, concerns about exogenous DNA permanently incorporated into the cells have limited development in this area.  More recently, several laboratories including our own have developed methods that result in iPSCs that are free of exogenous DNA.  Although important advances on the path to iPSC-based therapeutics have occurred, none of the methods developed to date enable efficient production of human cells so that they could be used as safe, efficacious and cost-effective therapeutics.  Work done in our laboratory and published in this article demonstrates such a process."

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development and personalized medicine applications.  CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools.  In addition, it is the leader in iPSC technology, the production of pluripotent stem cell lines from adult tissue.  CDI was founded in 2004 by Dr. James Thomson, a pioneer in human embryonic stem cell research at the University of Wisconsin-Madison.  CDI's facilities are located in Madison, Wisconsin. See www.cellulardynamics.com.


'/>"/>
SOURCE Cellular Dynamics International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11
2. MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting
3. Orange and Medic4all Launched the Worlds First Cellular Tele-Health Service
4. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
5. MIT, BU engineer cellular circuits that count events
6. New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the Worlds Leading Bioenergetics Researchers
7. Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement
8. iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming
9. Cellular Dynamics International Reprograms Blood Cells into Stem Cells
10. Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
11. Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics International
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... SAN DIEGO , March 29, 2017 /PRNewswire/ ... developing novel oncology and drug-delivery therapies, today announced ... U.S. Food and Drug Administration voted 11 to ... (under the skin) injection was favorable for patients ... large B-cell lymphoma and chronic lymphocytic leukemia. The ...
(Date:3/29/2017)... ... 2017 , ... Cancer diagnostics and pathology workflow solution provider ... Association of Community Cancer Centers (ACCC) 43rd Annual Meeting, CANCERSCAPE at ... stakeholders from leading national organizations to share insights on how value-based care, drug ...
(Date:3/29/2017)... NEWARK, Del. , March 29, 2017 ... medicine company, and W. L. Gore & ... announced a collaborative research agreement whereby the two companies ... delivery device technologies that provide protection from immune rejection. ... has been developing innovative stem cell-derived cell replacement therapies ...
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets ... Technologies and Global Markets" report to their offering. ... The ... DNA sequencing, biochips, RNA interference, synthetic biology tools and genome ... biologicals. These technologies and products are analyzed to ...
Breaking Biology Technology:
(Date:3/9/2017)... MELBOURNE , Australia , March ... clinical study data at the prestigious World Lung Imaging ... Dr. Andreas Fouras , was invited to deliver ... and pulmonary medicine. This globally recognised event brings together ... and share the latest developments in lung imaging. ...
(Date:3/7/2017)... March 7, 2017   HireVue , the leading ... companies identify the best talent, faster, today announced the ... Officer (CSO) and Diana Kucer as Chief ... seasoned executive team poised to drive continued growth in ... a year of record bookings in 2017. ...
(Date:3/2/2017)... 2, 2017 Summary This report ... Merck KGaA and its partnering interests and activities since ... Description The Partnering Deals and Alliance since 2010 ... of one of the world,s leading life sciences companies. ... purchase to ensure inclusion of the most up to ...
Breaking Biology News(10 mins):